Exicure to Present Poster at AAN 2019
SKOKIE, Ill.--(BUSINESS WIRE)--May 3, 2019--Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a poster presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, Pa. The poster is titled “Spherical Nucleic Acids Show Increased Distribution and Longer Persistence than Linear Oligonucleotides in Rat Brain Following IT Administration” and will be presented by Weston Daniel, Senior Director of Program Management at Exicure.
Session Date/Times: Sunday, May 5, 2019 from 11:30 a.m. to 6:30 p.m. ET
Presentation number: 6-032
Poster session 1: Child Neurology: Neurogenetics poster grouping within Poster Neighborhood Number 6
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure’s proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20190503005026/en/
KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS PENNSYLVANIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS PHARMACEUTICAL
SOURCE: Exicure, Inc.
Copyright Business Wire 2019.
PUB: 05/03/2019 07:00 AM/DISC: 05/03/2019 07:01 AM